Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Long-term Use Of Aspirin And Nonsteroidal Anti-inflammatory Drugs And Risk Of Colorectal Cancer.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Long-term Use Of Aspirin And Nonsteroidal Anti-inflammatory Drugs And Risk Of Colorectal Cancer.

    • Related Experiment Videos

    Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.

    Andrew T Chan1, Edward L Giovannucci, Jeffrey A Meyerhardt

    • 1Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA. achan@partners.org

    JAMA
    |August 25, 2005

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Regular, long-term aspirin use significantly reduces colorectal cancer risk, especially at higher doses. However, benefits are not seen until after a decade of use, and gastrointestinal bleeding risks increase with dose.

    Related Experiment Videos

    Area of Science:

    • Oncology
    • Epidemiology
    • Pharmacology

    Background:

    • Short-term aspirin use shows a causal link to reduced colorectal adenoma.
    • Limited data exists on long-term colorectal cancer risk with varying aspirin/NSAID doses, timing, or duration.

    Purpose of the Study:

    • To investigate the impact of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) on preventing colorectal cancer.

    Main Methods:

    • A prospective cohort study of 82,911 women from the Nurses' Health Study.
    • Biennial medication use data collected from 1980 to 2000, with follow-up through June 1, 2000.
    • Incident colorectal cancer cases were documented.

    Main Results:

    • Over 20 years, 962 colorectal cancer cases were observed.
    • Regular aspirin use (≥2 tablets/week) showed a relative risk (RR) of 0.77, with significant reduction after 10 years.
    • A dose-response relationship was found for both aspirin and nonaspirin NSAIDs, with higher doses and longer duration yielding greater risk reduction.
    • Higher aspirin doses correlated with increased gastrointestinal bleeding events.

    Conclusions:

    • Long-term, regular aspirin use effectively reduces colorectal cancer risk, similar to nonaspirin NSAIDs.
    • Significant benefits require over a decade of use, with optimal risk reduction at doses >14 tablets/week.
    • Higher aspirin doses for chemoprevention necessitate careful consideration of dose-related gastrointestinal bleeding risks.